Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 15, 2026, details the results of a Special Meeting of stockholders held by Catheter Precision, Inc. The meeting addressed critical capital structure matters, including the conversion of various series of preferred stock and a potential reverse stock split.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (March 9, 2026), the company had 2,357,127 shares of common stock outstanding. At the meeting, 1,165,698 shares were represented, constituting approximately 49.5% of outstanding shares. All six proposals presented were approved by the stockholders:
- Proposal 1: Approved issuance of common stock underlying Series C-1, C-2, C-3, and C-4 convertible preferred stock.
- Proposal 2: Approved issuance of common stock underlying Series D convertible preferred stock.
- Proposal 3: Approved issuance of common stock underlying Series J convertible preferred stock.
- Proposal 4: Approved issuance of additional common stock resulting from a reduction in the conversion price of Series B convertible preferred stock.
- Proposal 5: Approved an amendment to the Certificate of Incorporation to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-100, at the Board's discretion.
- Proposal 6: Approved the adjournment or postponement of the meeting if necessary to solicit additional votes.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the implications of the approved proposals. The approval of the reverse stock split (Proposal 5) indicates a strategic move to adjust the share price, though the specific ratio and timing remain at the Board's discretion.
Investor Verification Checklist
- Verify the exact number of new shares to be issued upon conversion of Series C, D, J, and B preferred stock.
- Monitor Board announcements regarding the specific ratio and effective date of the approved reverse stock split.
- Review the definitive proxy statement (Schedule 14A filed March 23, 2026) for detailed terms of the preferred stock conversions.
- Assess the impact of the increased share count from conversions on existing common stockholder dilution.